Search | Clinical Trials Finder

Conditions: Digestive Health, Quality of Life
Interventions: Fermented dairy protein with prebiotic fiber supplement, Control placebo; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Menopause, Healthy Female Participants
Interventions: Estradiol/Levonorgestrel Transdermal System; Drug
Lead sponsor: Corium Innovations, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy, Renal Insufficiency
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Anaheim, California • Pleasanton, California • Tustin, California + 3 more

Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Pain
Interventions: Suzetrigine, DRSP/EE, NGM/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Failure
Interventions: AMG 986; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Digestive Health, Quality of Life
Interventions: fermented dairy protein with prebiotic fiber; Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: HIV Infections
Interventions: VH4524184, Loestrin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: BMS-986165, diflunisal; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Refractory Autoimmune Diseases
Interventions: BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab; Genetic · Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Healthy
Interventions: Astaxanthin, Placebo; Dietary Supplement · Other
Lead sponsor: LycoRed Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Breast Cancer
Interventions: diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging; Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy, Renal Insufficiency
Interventions: Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more

Conditions: Healthy Volunteers
Interventions: Xanomeline/trospium chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy
Interventions: Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Cypress, California • South Miami, Florida • San Antonio, Texas

Conditions: Healthy Participants
Interventions: Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]); Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Search by objective public record fields.

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Protein-Prebiotic Wellbeing Study

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

A Study to Evaluate the Effect of Astaxanthin in Healthy Participants

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)